Artiva Biotherapeutics (NASDAQ:ARTV) COO Jennifer Bush Sells 8,370 Shares of Stock

Key Points

• COO Jennifer Bush sold 8,370 Artiva Biotherapeutics shares at an average price of $6.84, worth $57,250.80. The sale covered tax withholding tied to vested equity awards and reduced her holdings by 2.23% to 366,159 shares.
• Artiva’s stock recently traded at $7.27, with a market capitalization of approximately $355 million. The shares range from $2.71 to $14.53 over the past year, while the company remains unprofitable and analysts project a current-year loss of $2.62 per share.
• Analyst sentiment is broadly positive, with a consensus rating of “Moderate Buy” and an average price target of $39.00, despite ratings ranging from Sell to Strong Buy. Several institutional investors also initiated or increased positions in the second quarter.

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) COO Jennifer Bush sold 8,370 shares of Artiva Biotherapeutics stock in a transaction on Monday, October 5th. The stock was sold at an average price of $6.84, for a total value of $57,250.80. Following the sale, the chief operating officer owned 366,159 shares in the company, valued at $2,504,527.56. This trade represents a 2.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Artiva Biotherapeutics Stock Performance

NASDAQ:ARTV traded up $0.14 during trading on Tuesday, reaching $7.27. The company's stock had a trading volume of 664,480 shares, compared to its average volume of 393,650. Artiva Biotherapeutics, Inc. has a 12 month low of $2.71 and a 12 month high of $14.53. The firm has a market cap of $355.43 million, a price-to-earnings ratio of -2.20 and a beta of 2.40. The firm has a 50 day moving average of $10.09 and a 200-day moving average of $9.22.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.63) EPS for the quarter, hitting analysts' consensus estimates of ($0.63). Equities research analysts forecast that Artiva Biotherapeutics, Inc. will post -2.62 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Artiva Biotherapeutics

A number of large investors have recently made changes to their positions in ARTV. Squarepoint Ops LLC bought a new position in shares of Artiva Biotherapeutics during the second quarter valued at approximately $144,000. Spark Investment Management LLC bought a new stake in Artiva Biotherapeutics in the second quarter valued at $160,000. Alyeska Investment Group L.P. increased its position in Artiva Biotherapeutics by 173.6% during the 2nd quarter. Alyeska Investment Group L.P. now owns 273,615 shares of the company's stock valued at $2,654,000 after purchasing an additional 173,615 shares during the period. Nantahala Capital Management LLC purchased a new position in Artiva Biotherapeutics during the 2nd quarter valued at $2,910,000. Finally, 5AM Venture Management LLC bought a new position in Artiva Biotherapeutics in the 2nd quarter worth $22,827,049.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Needham & Company LLC reaffirmed a "buy" rating and issued a $41.00 price objective on shares of Artiva Biotherapeutics in a research report on Monday, June 8th. Wall Street Zen raised Artiva Biotherapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 8th. Cantor Fitzgerald restated an "overweight" rating and issued a $40.00 price objective on shares of Artiva Biotherapeutics in a research report on Friday. Weiss Ratings restated a "sell (d-)" rating on shares of Artiva Biotherapeutics in a research report on Tuesday, July 21st. Finally, HC Wainwright reissued a "buy" rating on shares of Artiva Biotherapeutics in a research note on Friday. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Artiva Biotherapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $39.00.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc NASDAQ: ARTV is a clinical-stage biotechnology company developing allogeneic natural killer (NK) cell therapies for cancer and autoimmune diseases. The company's approach is designed to produce off-the-shelf cell therapies that can be manufactured at scale and administered without using cells collected from each individual patient.

Artiva's lead investigational product, AlloNK, also known as AB-101, is an allogeneic NK cell therapy being evaluated in combination with rituximab for autoimmune conditions, including systemic lupus erythematosus and lupus nephritis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.